Adjuvant Pharmacological Therapy for HAD

Several drugs have been tested as adjunctive agents for the therapy of HAD. This section mainly describes medications that have been subject to clinical trials, with a brief description of other potentially promising compounds. 

Memantine is a competitive inhibitor of the A/-methyltaspar-tate glutamate receptor (NMDA). Clinically, memantine has been effective in the treatment of Alzheimer s dementia and 

To date, one clinical dial has evaluated the role of nimocUpine in the heatment of HAD. A multicenter phase I/II study by the AIDS CUnical Trial Group enrolled 4l patients with cUfferent degrees of HAD (Navia et al., 1998). Patients were assigned to one of three arms placebo, nimocUpine 30mg orally del or nimocUpine 50 mg five times a clay for 16 weeks. Patients in all arms received an NRTI (ziclovucUne, cUclanosine 

---